Scarica l'app Stockscreener
1.65
3.12%
0.05
Dopo l'orario di chiusura:
1.67
0.02
+1.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BTAI Giù?
Forum
Previsione
Bioxcel Therapeutics Inc Borsa (BTAI) Ultime notizie
BTAI PE Ratio & Valuation, Is BTAI Overvalued - Intellectia AI
BTAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AI Drugmaker BioXcel Eyes $9.8M Investor Settlement - Law360
BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioXcel Submits sNDA for Igalmi to Treat Agitation - Intellectia AI
Is BioXcel Therapeutics Inc. stock good for income investorsJuly 2025 Rallies & Risk Controlled Stock Alerts - mfd.ru
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia - Bitget
BioXcel Therapeutics (BTAI) Hosts Roundtable on Acute Agitation in Alzheimer's - GuruFocus
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia - The Manila Times
Doctors tackle 100M Alzheimer’s agitation episodes in new BioXcel webcast - Stock Titan
Why BioXcel Therapeutics Inc. stock is favored by pension fundsJuly 2025 Macro Moves & Advanced Technical Analysis Signals - mfd.ru
Aug Weekly: Is BioXcel Therapeutics Inc gaining market shareTrade Exit Report & Safe Swing Trade Setups - baoquankhu1.vn
BioXcel Therapeutics Reports Successful Primary Endpoint Achievement in SERENITY At-Home Phase 3 Safety Trial, Supporting sNDA for IGALMI® Label Expansion - Intellectia AI
Can BioXcel Therapeutics Inc. stock hit record highs againBond Market & Weekly Breakout Opportunity Watchlist - mfd.ru
BTAI Should I Buy - Intellectia AI
What earnings margins imply for BioXcel Therapeutics Inc. (BX20) stockJuly 2025 Levels & Daily Momentum Trading Reports - mfd.ru
Movement Recap: Is BioXcel Therapeutics Inc. benefiting from interest rate changes2025 Top Decliners & AI Driven Stock Movement Reports - mfd.ru
Bioxcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for Igalmi in the At-Home Setting - marketscreener.com
BioXcel Therapeutics (BTAI) Advances with Igalmi for At-Home Use - GuruFocus
BioXcel Highlights IGALMI At-Home Acute Agitation Opportunity - TipRanks
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting - The Manila Times
BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI in the At-Home Setting - Bitget
BioXcel Therapeutics Completes Market Assessment for IGALMI - TradingView
BioXcel Therapeutics Completes Market Opportunity - GlobeNewswire
How cyclical is BioXcel Therapeutics Inc.’s revenue streamPortfolio Gains Report & High Accuracy Buy Signal Tips - mfd.ru
Aug Selloffs: What are the risks of holding BioXcel Therapeutics Inc.Weekly Volume Report & Consistent Growth Stock Picks - mfd.ru
Is BioXcel Therapeutics Inc.’s growth already priced inWeekly Gains Summary & Weekly Watchlist for Hot Stocks - mfd.ru
BioXcel Therapeutics announces milestone and retention bonuses for key executives - Investing.com
BioXcel sets milestone bonuses amid pivotal IGALMI review - TipRanks
CEO Moves: What is GMFIWs 5 year growth outlookTrade Entry Report & Community Supported Trade Ideas - baoquankhu1.vn
Rate Hike: Is BioXcel Therapeutics Inc gaining market share2025 Key Highlights & Growth Focused Entry Reports - baoquankhu1.vn
Movement Recap: Is BioXcel Therapeutics Inc. stock a falling knife or bargain buyJuly 2025 Opening Moves & Stepwise Trade Signal Guides - mfd.ru
BioXcel Says Doctor Sent Fake Email About Alzheimer's Trial - Law360
BioXcel Therapeutics submits sNDA for at-home use of IGALMI By Investing.com - Investing.com South Africa
BioXcel seeks FDA approval for at-home IGALMI use - The Globe and Mail
BioXcel Therapeutics (BTAI) Advances Igalmi's Reach with FDA Sub - GuruFocus
BioXcel Therapeutics submits application to expand IGALMI use for at-home treatment - Investing.com Nigeria
BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting - The Manila Times
BioXcel Therapeutics Submits Supplemental NDA To US FDA For IGALMI® At-Home Label Expansion - TradingView
BioXcel Therapeutics submits sNDA for at-home use of IGALMI - Investing.com
BioXcel Therapeutics Submits sNDA for IGALMI® At-Home Use - TradingView
What are the risks of holding BioXcel Therapeutics Inc.Weekly Trade Report & Capital Protection Trading Alerts - bollywoodhelpline.com
How BioXcel Therapeutics Inc. (BX20) stock moves on employment data2025 Fundamental Recap & Weekly Breakout Watchlists - bollywoodhelpline.com
Ag Plus, Inc. - Ag Plus, Inc.
Palmetto Grain Brokerage - Palmetto Grain Brokerage
1 Top Penny Stock to Watch Now - Yahoo Finance
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
BioXcel adds chief commercial officer as it prepares to expand agitation drug IGALMI’s reach - Hartford Business Journal
VIX Spike: Can BioXcel Therapeutics Inc. stock maintain growth trajectoryTrade Entry Report & Smart Swing Trading Alerts - Bộ Nội Vụ
BioXcel Therapeutics Appoints Mark Pavao as Interim Chief Commercial Officer - citybiz
Returns Recap: Is BioXcel Therapeutics Inc benefiting from interest rate changesJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
BioXcel Therapeutics names interim CCO amid IGALMI expansion - TipRanks
BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting - The Manila Times
0.21%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):